Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
When Shire bought out Dyax for up to $6.5 billion in 2015, the big prize was a new drug for hereditary angioedema dubbed DX-2930 which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
